Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Octreotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 known ✓ | P30874 | 13/20 | 0.95 |
| ▸ | SSTR5 known ✓ | P35346 | 13/20 | 0.95 |
| ▸ | SSTR4 known ✓ | P31391 | 9/20 | 0.95 |
| ▸ | SSTR3 known ✓ | P32745 | 5/20 | 0.84 |
| ▸ | SSTR1 known ✓ | P30872 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octreotide SCHEMBL15856937 | 0.97 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL17404479 | 0.97 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL10044649 | 0.97 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL18823378 | 0.97 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL17404705 | 0.97 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL23424109 | 0.97 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL18823377 | 0.97 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL21944070 | 0.97 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL21840389 | 0.97 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL17404626 | 0.97 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017134655-A1 | IMPROVED ORAL ABSORPTION OF OCTREOTIDE AND SALTS THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-08-10 | — | — | WO | claimed |
| EP-3713545-A1 | THERAPEUTIC COMPOUND FORMULATIONS | Dauntless 1, Inc. (US) | 2020-09-30 | — | — | EP | disclosed |
| US-20200281857-A1 | THERAPEUTIC COMPOUND FORMULATIONS | Dauntless 1, Inc. (US) | 2020-09-10 | — | — | US | disclosed |
| WO-2019104225-A1 | THERAPEUTIC COMPOUND FORMULATIONS | DAUNTLESS 2, INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| WO-2017134655-A1 | IMPROVED ORAL ABSORPTION OF OCTREOTIDE AND SALTS THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-08-10 | — | — | WO | disclosed |
| US-20100240865-A1 | PROCESS FOR PRODUCTION OF CYCLIC PEPTIDES | TOVI AVI | 2010-09-23 | — | — | US | disclosed |
| US-20100137559-A1 | PROCESS FOR PRODUCTION OF CYCLIC PEPTIDES | TOVI AVI | 2010-06-03 | — | — | US | disclosed |
| EP-1709065-B1 | A COUNTERION EXCHANGE PROCESS FOR PEPTIDES | NOVETIDE LTD (IL) | 2010-06-02 | — | — | EP | disclosed |
| EP-2163558-A2 | A Counterion Exchange Process for Peptides | Novetide Ltd. (IL) | 2010-03-17 | — | — | EP | disclosed |
| EP-1709065-A2 | A COUNTERION EXCHANGE PROCESS FOR PEPTIDES | Novetide Ltd. (IL) | 2006-10-11 | — | — | EP | disclosed |
| EP-1511761-B1 | PROCESS FOR PRODUCTION OF CYCLIC PEPTIDES | NOVETIDE LTD (IL) | 2006-08-02 | — | — | EP | disclosed |
| US-20060148699-A1 | Counterion exchange process for peptides | TEVA PHARMACEUTICALS USA, INC. | 2006-07-06 | — | — | US | disclosed |
| WO-2006041945-A2 | A COUNTERION EXCHANGE PROCESS FOR PEPTIDES | NOVETIDE, LTD. (IL) | 2006-04-20 | — | — | WO | disclosed |
| EP-1511761-A1 | PROCESS FOR PRODUCTION OF CYCLIC PEPTIDES | Novetide Ltd. (IL) | 2005-03-09 | — | — | EP | disclosed |
| US-20040249121-A1 | Process for production of cyclic peptides | NOVETIDE, LTD. (IL) | 2004-12-09 | — | — | US | disclosed |
| WO-2004092202-A1 | PROCESS FOR PRODUCTION OF CYCLIC PEPTIDES | NOVETIDE, LTD. (IL) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148699-A1 | Counterion exchange process for peptides | VIP, NPPA, SLC26A3 | SSTR2 84/4885SSTR5 16/4885SSTR4 11/4885 |
| US-20200281857-A1 | THERAPEUTIC COMPOUND FORMULATIONS | HDAC6, THPO, ALG1 | SSTR2 89/4885SSTR5 72/4885SSTR4 188/4885 |
| US-20100137559-A1 | PROCESS FOR PRODUCTION OF CYCLIC PEPTIDES | VIP, NPPA, IAPP | SSTR2 161/4885SSTR5 28/4885SSTR4 45/4885 |
| US-20100240865-A1 | PROCESS FOR PRODUCTION OF CYCLIC PEPTIDES | VIP, NPPA, IAPP | SSTR2 161/4885SSTR5 28/4885SSTR4 45/4885 |
| US-20040249121-A1 | Process for production of cyclic peptides | VIP, NPPA, IAPP | SSTR2 161/4885SSTR5 28/4885SSTR4 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.